GLP-3 RT (10mg)
Technické špecifikácie
| Čistota (HPLC) | ≥97% (HPLC) |
| CAS číslo | 2381089-83-2 |
| Forma | White lyophilized powder |
| Skladovanie | -20°C |
| Sekvencia | Modified triple incretin agonist |
| Molekulová hmotnosť | 4,803.56 g/mol |
| Soľná forma | Acetate |
| Rozpustnosť | Soluble in aqueous buffer |
GLP-3 RT (10mg)
Katalógová cena v EUR · HU, SK, CZ, PL
- Eurozone (EUR)252,00 EUR
- Maďarsko (HU)252,00 EUR≈ 100 800 Ft
- Slovensko (SK)252,00 EUR
- Česko (CZ)252,00 EUR≈ 6 300 Kč
- Poľsko (PL)252,00 EUR≈ 1071,00 zł
Rovnaká katalógová cena v EUR pri doručení do Maďarska, Slovenska, Česka a Poľska. Platba v EUR.
Orientačné HUF/CZK/PLN prepočítané z EUR; Slovensko používa EUR. Kurzy približné. Platba v EUR.
Triple agonist (GLP-1/GIP/Glucagon) for metabolic research.
Mechanism: GLP-1 (appetite), GIP (insulin sensitivity), Glucagon (thermogenesis).
Applications: Obesity, NAFLD/NASH, metabolic syndrome.
Protocol: Reconstitute 2ml BAC water. Store -20°C. Do not vortex.
Len na laboratórny výskum.
Nie je určené na ľudskú spotrebu, veterinárne ani diagnostické použitie.
From the Peptide Explorer
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Key Mechanisms
- ›GIP receptor agonism
- ›GLP-1 receptor agonism
- ›Glucagon receptor agonism (energy expenditure)
- ›Hepatic lipid metabolism enhancement
- ›Appetite suppression via CNS pathways
Primary Research Areas
- ›Obesity
- ›NASH
- ›Metabolic syndrome
- ›Triple-incretin signaling
- ›Energy expenditure
Key Research Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Overview
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Origin: Triple GIP/GLP-1/glucagon receptor agonist by Eli Lilly
Mechanism of Action
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism (energy expenditure)
- Hepatic lipid metabolism enhancement
- Appetite suppression via CNS pathways
Primary Research Areas
- Obesity
- NASH
- Metabolic syndrome
- Triple-incretin signaling
- Energy expenditure
Key Published Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
2-8°C
Important Notice
Retatrutide (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Výskumné špecifikácie
Synthesized for strict analytical consistency. Verified via HPLC/MS.Zobraziť štandardy kvality →
Manipulácia a skladovanie
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in aqueous buffer
Časté otázky
What is GLP-3 RT (10mg)?▼
Is GLP-3 RT (10mg) intended for human consumption?▼
How do you verify purity and identity?▼
How should GLP-3 RT (10mg) be stored?▼
Do you provide a Certificate of Analysis (COA)?▼
What purity is GLP-3 RT (10mg)?▼
Verified Research Reviews
Reta is amazing
"really amazing compound and interesting "